Webinar: Keeping Students and Communities Safe with School-based Flu and COVID-19 Testing
As students return to classrooms, schools face the combined challenges of the surging variants, students too young to receive a vaccine, and the flu season. BD is partnering with NAESP to host a webinar discussing the benefits of asymptomatic screening of COVID-19 using rapid antigen serial testing. This testing can help limit outbreaks and keep schools open. The webinar will share best practices on how to set up an effective and efficient process for testing in schools, as well as options for testing that quickly and efficiently delivers results on COVID-19 and Flu A+B.
• An overview of how rapid antigen coronavirus testing such as the BD Veritor™ Plus System works
• An understanding of how rapid antigen testing can help keep schools open and students safe
• Best practices on how to set up an effective and efficient process for testing in schools
This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories;
This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. For more information, please see bdveritor.com.